Clinicopathological Value of p16 Expression in Colorectal Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Immunohistochemical staining.
- Who it may be relevant to
- Registry conditions: Colorectal Carcinoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinicopathological Value of p16 Expression in Colorectal Carcinoma: An Immunohistochemical Study.
Overview
Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.
Detailed description
Colorectal Carcinoma is very common nowadays, with increasing need for further research.
p16 is tumor suppressor gene with a vital rule ; inactivation of p16 leads to tumor formation and progression.
50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.
The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type, grade and stage of each tumor.
Another sliced tissue sections will be immunohistochemically stained with p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Interventions
- Biological Immunohistochemical staining
Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Primary outcome measures
- Evaluation of p16 Expression in Colorectal Carcinoma. [Time frame: 6 months]
Secondary outcome measures (1)
- Correlation of p16 expression to different clinical and pathological parameters [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Specimens from patients with colorectal cancer.
- Tissue blocks with sufficient material.
- Specimens with sufficient clinical data.
Exclusion criteria
- Tissue blocks with insufficient, destroyed or necrotic material.
- Specimens with insufficient clinical data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Egypt · 1 center
- Faculty of Medicine — Sohag
Identifiers
NCT: NCT07047482 · Soh-Med--25-6-2MS